Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tokyo-Based Lion Changes Bufferin Distributor From BMS To Eisai

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Lion Corp, Bristol-Myers K.K and Eisai agreed May 12 to change the distributor of bufferin 81 mg and 330 mg tablets from BMKK to Eisai. Lion owns the manufacturing and marketing rights in Japan. Eisai has been actively promoting drugs that are combined with bufferin to treat cardiovascular disease. The distribution agreement will further strengthen Eisai's sales to medical facilities. Lion will continue to manufacture and sell the over-the-counter bufferin in Japan. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts